Compared with a combination treatment of LABA/LAMA, ICS/LABA/LAMA combination therapy was associated with a significantly greater pooled risk reduction in COPD exacerbation.
Few individuals hospitalized for COPD receive pulmonary rehabilitation.
Three-dimensional "super clusters" in patients with COPD could play a role in the progression of COPD to emphysema.
There may an increased risk for tuberculosis in patients with COPD within 3 years of inhaled corticosteroid use.
The FDA has approved Yupelri inhalation solution for the maintenance treatment of patients with COPD.
The overall rate of asthma-COPD overlap was 3.8%, with a maximum prevalence of 7.8% in Matlab, Bangladesh.
Adults with COPD treated with both inhaled corticosteroids and low-dose theophylline as adjunct therapy did not have fewer exacerbations compared with patients treated with inhaled corticosteroids only.
Half of patients with COPD report use of inhaler medications that are not in alignment with the current treatment recommendations.
Air-driven bronchodilator nebulization is preferable to oxygen-driven nebulization in patients experiencing acute COPD exacerbations.
The increased occurrence of periprocedural complications in patients with COPD was largely attributed to cardiac arrest, myocardial infarctions, and no-reflows.
Albuminuria was associated with greater lung function decline in patients with chronic obstructive pulmonary disease.
No difference in mortality, but there may be an elevated risk for suicide with long-term benzodiazepine use in patients with COPD and comorbid PTSD.
Middle-aged testosterone replacement therapy users with COPD had a greater reduction in hospitalizations compared with nonusers.
Early pulmonary rehabilitation after hospitalization for an acute exacerbation of COPD was an effective intervention for reducing mortality.
The FDA has approved updated labeling for Stiolto Respimat to include COPD exacerbation data and a revised indication.
Patients with severe COPD improved significantly in both endurance time and walking distance with the use of automatically titrated oxygen flow vs constant oxygen flow.
Treatment with prophylactic antibiotics was associated with a reduction in the frequency of COPD exacerbations and improved quality of life.
No meaningful associations were detected in procedural listing preferences and survival outcomes in patients with COPD or interstitial lung disease awaiting lung transplant.
Clinicians are eager for new therapies to address the damage to airways and lung parenchyma because no current therapy can completely reverse COPD damage.
After 12 months, patients in the Urban Training™ group had increased their number of daily steps by 816 compared with 64 steps in the usual care group.
Additional bronchodilation and hyperinflation reduction occurred in COPD when RPL554, an inhaled PDE 3 and 4 inhibitor, was combined with standard bronchodilators.
Changing pollination patterns, extreme weather events, rising sea levels, air pollution, and extreme temperatures all negatively affect respiratory conditions.
There were no statistically significant differences in mortality rates, rates of COPD exacerbations, lung inflammation, or serious adverse events between a once-daily combined inhaled corticosteroid/LABA and LAMA.
A total of 35% of heroin smokers screened positive for COPD.
Pooled data from two identical 12-week pivotal Phase 3 trials (N=1229) in patients with moderate to very severe COPD showed that the mean annualized rate of all COPD exacerbations was 0.47, 0.45, and 0.55 for revefenacin 175mcg/day, 88mcg/day, and placebo, respectively.
No difference in exacerbations with indacaterol/glycopyrronium for non-frequently exacerbating COPD.
First bronchoscopic lung volume reduction using endobronchial valve performed at Temple University in Philadelphia, PA.
In their Complete Response Letter, the FDA stated that they require more clinical data to support approval.
Cardiovascular risk within 30 days of therapy start was approximately 2-fold higher with the incident use of tiotropium in COPD.
In patients with emphysema, deposition fraction was significantly lower than in other individuals, but no significant differences were found between healthy never smokers and current or former smokers.
Thigh muscle volume showed significant improvements in patients with COPD who were treated with bimagrumab vs placebo.
Patients with COPD who have comorbidities are less likely to receive beneficial treatment for exacerbations.
The incidence of undiagnosed COPD was 26%, and based on the GOLD spirometry grading system, 95% had mild to moderate disease.
Although the summer season yielded the lowest overall COPD exacerbation rate, 43% of exacerbations during summer were moderate to very severe.
The average annual prevalence of bronchiectasis from 2012 to 2014 was 701 cases per 100,000 individuals.
S pneumoniae colonization was positively associated with H influenza colonization, whereas negative associations were reported between P aeruginosa and H influenzae and between P aeruginosa and M catarrhalis.
Comorbid chronic rhinitis is significantly associated with 30-day hospital readmissions related to asthma and chronic obstructive pulmonary disease.
Prior use of systemic corticosteroids and prior isolation of Pseudomonas aeruginosa were risk factors associated with the presence of Pseudomonas aeruginosa in COPD.
Short-term corticosteroids may be sufficient for treating patients with acute COPD exacerbations.
Patients with COPD who had a relative lymphocyte count ≤20% had a higher risk for mortality.
When compared with a placebo control cannabis, cannabis had no effect on breathlessness intensity ratings during exercise at isotime or on exercise endurance time.
Shorter telomere length was associated with worse health status in chronic obstructive pulmonary disease, as measured by St. George's Respiratory Questionnaire.
Anxiety symptoms are more common in patients with COPD as determined by the Generalized Anxiety Disorder, Hospital Anxiety and Depression scale, and Anxiety Inventory for Respiratory Disease screening questionnaires vs the DSM-V criteria.
Although emerging data offer valuable clues, the pathophysiological distinctions between different phenotypes of chronic obstructive pulmonary disease are still poorly understood.
Mortality was significantly increased among patients with rheumatoid arthritis and COPD.
Patients who were hospitalized for non-severe acute exacerbations of COPD did not experience improved outcomes when antibiotics were administered for longer than 24 hours.
NT-proBNP may be an independent predictor of respiratory exacerbations in patients with COPD even without overt cardiovascular disease.
Collagen biomarkers were significantly higher at extreme exacerbations, and were also associated with circulating adrenomedullin.
Rates of pulmonary embolism ranged from 3.3% to 29.1% in patients with a clinical diagnosis of an acute exacerbation of COPD.
There were differences in use of steroids and antibiotics noted between teaching and non-teaching hospital staff.
Whole-genome sequencing was valuable in identifying a large number of potentially significant functional variants in severe COPD.
Although COPD has been identified as a risk factor for cardiovascular disease, researchers are less certain about the relationship between COPD and stroke.
Frequent asthma, bronchitis, allergy demonstrated the strongest association with , lower FEV1, lower FEV1/forced vital capacity, and increased risk for COPD.
Dexamethasone was not effective in reducing the incidence of acute mountain sickness and altitude-related adverse health effects in individuals with mild to moderate COPD.
Regardless of renal impairment, combination therapy with tiotropium/olodaterol was safe and tolerable in patients with moderate to very severe COPD.
Study authors performed a post hoc pooled analysis of data from 10 trials to assess the safety and efficacy of umeclidinium/vilanterol in elderly symptomatic patients with COPD.
Gastroesophageal reflux disease is associated with an increase in bronchitis symptoms in patients with COPD.
The approval was based on results from a multicenter study (LIBERATE) of 190 patients with severe emphysema.
For patients with advanced COPD, the use of formal palliative care services and long-term oxygen therapy has increased but remains low.
The clinical significance of emphysema was greater in people living with HIV vs those without HIV.
The use of formal palliative care services among patients with chronic obstructive pulmonary disease increased by 1% per year, going from 5.3% in 2004 to 14.3% in 2014.
A 72-year-old man with a 50 pack-year smoking history and multiple comorbidities, including COPD, presents to the emergency department with left-sided hemiparesis and sensory loss.
There was as significant change in Bristol COPD Knowledge Questionnaire scores in patients who received a brief education program at the time of an acute exacerbation of COPD.
Acute COPD exacerbations were associated with an increased risk for myocardial infarction and ischemic stroke.
Zephyr® Endobronchial Valve EBV® treatment improved FEV1 in patients with heterogeneous emphysema.
The inclusion of residual volume-to-total lung capacity ratio may add another dimension to COPD not routinely captured by standard airflow indices that could be predictive of lower maximum exercise capacity.
A direct de-escalation from triple therapy to indacaterol/glycopyrronium may be appropriate in patients with infrequent COPD exacerbations.
A definition of a pulmonary vascular phenotype of chronic obstructive pulmonary disease has been proposed.
Recent research suggests that increasing obesity class is independently associated with worse respiratory-specific and general quality of life outcomes in COPD.
PHQ-9 and PHQ-2 show factorial validity, invariance, and reliability for measuring depression in patients with chronic obstructive pulmonary disease.
Emerging guidelines for diagnosing and treating asthma COPD overlap syndrome will help clinicians better manage patients and prevent serious adverse effects.
Survival at 6 months was significantly associated with acute respiratory failure and history of COPD.
A higher proportion of patients with COPD and a blood eosinophil count of ≥0.34×109/L had elevated markers of low-grade systemic inflammation regardless of forced expiratory volume in 1 second.
Readmission rates were highest during the first 72 hours after admission for an acute exacerbation of chronic obstructive pulmonary disease.
Adding olodaterol to tiotropium did not significantly reduce exacerbations in patients with chronic obstructive pulmonary disease as much as researchers had anticipated.
Asthma and COPD overlap linked to higher prevalence of sleep-related symptoms, including difficulty falling asleep and maintaining sleep, early-morning awakening, and excessive daytime sleepiness.
The drug consists of fluticasone furoate, an inhaled corticosteroid (ICS), umeclidinium, a long-acting muscarinic antagonist, and vilanterol, a long-acting beta2-adrenergic agonist (LABA), delivered via an Ellipta dry powder inhaler.
In patients with COPD, transcatheter aortic valve replacement was associated with fewer respiratory-related complications than surgical aortic valve replacement.
Statins have anti-inflammatory and anti-oxidative effects, which could reduce exacerbations of both asthma and chronic obstructive pulmonary disease.
Triple therapy with fluticasone furoate, umeclidinium, and vilanterol was associated with a lower rate of exacerbations in chronic obstructive pulmonary disease.
A childhood measles infection may increase the risk for post-bronchodilator airflow obstruction in middle-age adults via its interaction with asthma and smoking.
A 55-year-old man with chronic obstructive pulmonary disease reports having some mild chest pain.
A 64-year-old man with chronic obstructive pulmonary disease, diabetes, chronic kidney disease, and morbid obesity seeks preoperative approval for femoral popliteal bypass surgery.
Treating chronic obstructive pulmonary disease remains challenging, particularly in terms of choosing the appropriate fixed-dose combination bronchodilator.
Tai chi found to be as effective as pulmonary rehabilitation for patients with chronic obstructive pulmonary disease.
It is still not known whether differences in mortality rates between patients who receive noninvasive vs invasive ventilation for acute exacerbations of COPD can be attributed to less severe disease or other factors.
Researchers identified 6 distinct FEV1 lung function trajectories, 3 of which were responsible for 75% of the COPD burden.
Lonhala Magnair is available as a 25mcg strength inhalation solution per 1mL vial.
Peak flow meter, microspirometry are optimal, with full spirometry for positive results.
Sleep quality in patients with chronic obstructive pulmonary disease may be a significant predictor of multiple metrics of quality of life.
Study authors concluded, "Combining tiotropium and olodaterol did not reduce exacerbation rate as much as expected compared with tiotropium alone."
Disease management added to recommended care in chronic obstructive pulmonary disease was not superior to recommended care alone.
Four different doses of glycopyrronium delivered via metered dose inhaler were compared for safety and efficacy in the treatment of chronic obstructive pulmonary disease.
The Clinical COPD Questionnaire cutoff point of 1.4 demonstrated a better agreement with other COPD measures in patients with more symptomatic disease.
Patients with chronic obstructive pulmonary disease with 5% emphysema based on thoracic computed tomography (CT) imaging may be at a greater risk for poor outcomes.
Combination treatment with indacaterol-glycopyrronium may improve cardiac function in patients with chronic obstructive pulmonary disease.
Individuals with chronic obstructive pulmonary disease who met physical activity guidelines experienced the greatest reductions in all-cause, CVD, and respiratory mortality risk.
Intermittent use of high-dose glucocorticoids did not increase the risk for fracture in patients with COPD.
Independent predictive factors of lung cancer in chronic obstructive pulmonary disease may include frequency of exacerbations, in addition to airflow obstruction and visual emphysema.
Researchers used data from the Atherosclerosis Risk in Communities Study to assess associations between dietary pattern and pulmonary assessments.